Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 2898-2909

  Duong, Le T ^a   Wesolowski, Gregg A ^a   Leung, Patrick ^a   Oballa, Renata ^b   Pickarski, Maureen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Inception Sciences Canada Inc ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; CATHEPSIN K INHIBITOR; L 235; MESSENGER RNA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE TUMOR; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PREVENTION; CANCER SIZE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; EX VIVO STUDY; HISTOLOGY; HUMAN; HUMAN CELL; IC50; LOCAL METASTASIS; NONHUMAN; OSTEOLYSIS; RADIOGRAPHY; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; BREAST TUMOR; CANCER GRADING; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CATHEPSIN K; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM METASTASIS; OSTEOLYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917705814     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0253     Document Type: Article

References (29)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 2010;7:641-51.
4. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2012;2:CD003474.
5. Coleman RE, Costa AL, Cook RJ, Lee K-A, Saad F, Brown JE, et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features - An exploratory analysis of placebo-controlled trials. J Bone Oncol 2013;2:70-6.
6. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
8. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-93.
9. Bromme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996;271:2126-32.
10. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
11. Duong LT. Therapeutic inhibition of cathepsin K-reduction of bone resorption while maintaining bone formation. Bone KEy 2012;67:3-8.
12. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011;7:447-56.
13. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003;18:222-30.
14. Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997;57:5386-90.
15. Le Gall C, Bellahcene A, Bonnelye E, Gasser JA, Castronovo V, Green J. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894-902.
16. Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010;10:452-8.
17. Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, et al. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J Med Chem 2005;48:7520-34.
18. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-8.
19. Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005;48:7535-43.
20. Desmarais S, Black WC, Oballa R, Lamontagne S, Riendeau D, Tawa P, et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol 2008;73:147-56.
21. Pennypacker BL, Duong LT, Cusick TE, Masarachia PJ, Gentile MA, Gauthier JY, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2011;26:252-62.
22. Simoni D, Gebbia N, Invidiata FP, Eleopra M, Marchetti P, Rondanin R, et al. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem 2008;51:6800-7.
23. Ferguson VL, Simske SJ, Ayers RA, Bateman TA, Wang HT, Bendele A, et al. Effect of MPC-11 myeloma and MPC-11 + IL-1 receptor antagonist treatment on mouse bone properties. Bone 2002;30:109-16.
24. Le Gall C, Bonnelye E, Clezardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008;2:218-22.
25. Altmann E, Renaud J, Green J, Farley D, Cutting B, Jahnke W. Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. J Med Chem 2002;45:2352-4.
26. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007;13:387-403.
27. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75.
28. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012;27:524-37.
29. Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P, Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2002;101:135-48.